ClinicalTrials.gg
RecruitingNCT06506513MYO-MASLDUpdated Jul 14, 2026

Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

An interventional study of High-intensity interval training and Moderate intensity exercise training in Metabolic Dysfunction-associated Steatotic Liver Disease, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Recruiting at 2 sites in Belgium. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 148 studies in Motor Activity with a site in Belgium — 40 open to participants now, 44 under way, none of them phase 3. Motor Activity · Belgium.

Planned enrollment
58th of 117
60 · median 60
Started
2025
with 10 others
No phase
107 of 148
30 open now
Primary completion
2027-09
later than 31 of 43 live
Registered
122nd of 148
by date
Lead sponsor
7 of 148
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Among the 148 studies in Motor Activity with a site in Belgium, this one is the 58th largest by planned enrollment of the 117 interventional ones that give a count, is one of 11 that started in 2025, is one of 107 with no phase, reaches primary completion later than 31 of the 43 other live ones, and was the 122nd registered.

Motor Activity

9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.

Browse Motor Activity studies →

Open to participants now

40 of the 148 studies in Motor Activity with a site in Belgium are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 1,201 Motor Activity studies recruiting now, 517 (43%) set no upper age limit and 535 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Motor Activity with a site in Belgium, or all of them as a file.
02

Study summary

Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.

Read the detailed description

In this monocenter interventional study, we will assess the impact of physical activity on muscle fat content and liver disease severity in MASLD as well as the mechanisms mediating the potential beneficial effects of exercise.

03

Conditions studied

  • Metabolic Dysfunction-associated Steatotic Liver Disease

Browse trials for

Keywords

  • metabolic dysfunction-associated steatotic liver disease
  • MASLD
  • physical activity
  • myosteatosis
  • magnetic resonance imaging
  • magnetic resonance specroscopy
  • muscle biopsy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed MASLD at abdominal imaging
  • confirmed excessive muscle lipid content at imaging
  • stable weight

Exclusion criteria

Exclusion Criteria:

  • severe comorbidities including active , neuromuscular degenerative diseases
  • to physical activity
  • excessive alcohol consumption
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    control group

    in this control group, patients will perform non-cardiovascular non-intensity training (stretching, meditation).

    Other: Low intensity exercise training

  • Active comparator
    moderate-intensity low interval training group

    In this group, patients will perform moderate-intensity low interval training.

    Other: Moderate intensity exercise training

  • Active comparator
    high-intensity interval training

    In this group, patients willp erform high-intensity interval training.

    Other: High-intensity interval training

Interventions

  • OtherHigh-intensity interval training

    High-intensity interval training

  • OtherModerate intensity exercise training

    Moderate intensity exercise training

  • OtherLow intensity exercise training

    Low intensity exercise training

06

What researchers measure

Primary outcomes

  1. the impact of physical activity on muscle and liver phenotypes

    the investigators will assess at baseline and every four weeks till study completion the impact of intervention on liver phenotype assessed by transient elastography and muscle phenotype assessed by MRI

    Time frame: every four weeks from baseline till study completion

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Henin G, Loumaye A, Leclercq IA, Lanthier N. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 2023 Nov 14;6(2):100963. doi: 10.1016/j.jhepr.2023.100963. eCollection 2024 Feb. PubMed 38322420 ↗
  • Henin G, Loumaye A, Deldicque L, Leclercq IA, Lanthier N. Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction-associated steatotic liver disease? Liver Int. 2024 Aug;44(8):1781-1796. doi: 10.1111/liv.15938. Epub 2024 Apr 16. PubMed 38623714 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 5,147 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 24 months is above that.

Counting every sponsor, half of 5,207 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 17, 2024
StartActual
Sep 1, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06506513
Collaborators
Concerted Research Action, Fonds National de la Recherche Scientifique
Responsible party
Sponsor
First posted
Jul 17, 2024
Start date
Sep 1, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Guillaume Henin, MD, PhD student
Contact
guillaume.henin@uclouvain.be
0032494312548
Nicolas Lanthier, MD, PhD
Contact
nicolas.lanthier@saintluc.uclouvain.be
003227647089
Nicolas Lanthier, MD, PhD
principal investigator · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion